

ABSTRACT

The present invention is related with the use of vinpocetine and the derivatives developed from its formula that maintains the same effects for the treatment of epilepsy and its complications. Our results show that vinpocetine prevents all the abnormalities of the ABR waves that accompany the epileptic cortical activity observed for the ictal and post-ictal periods in two experimental models of epilepsy in vivo, that vinpocetine also inhibits the marked hearing loss and the characteristic EEG changes induced by two convulsing agents that differ in their mechanisms of action. These findings also indicate that the capacity of vinpocetine as an antiepileptic drug is not accompanied by adverse secondary effects.